178 related articles for article (PubMed ID: 28790113)
1. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
2. Neurotensin receptor1 antagonist SR48692 reduces proliferation by inducing apoptosis and cell cycle arrest in melanoma cells.
Zhang Y; Zhu S; Yi L; Liu Y; Cui H
Mol Cell Biochem; 2014 Apr; 389(1-2):1-8. PubMed ID: 24357116
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of neurotensin receptor 1 induces intrinsic apoptosis via let-7a-3p/Bcl-w axis in glioblastoma.
Dong Z; Lei Q; Yang R; Zhu S; Ke XX; Yang L; Cui H; Yi L
Br J Cancer; 2017 Jun; 116(12):1572-1584. PubMed ID: 28494471
[TBL] [Abstract][Full Text] [Related]
4. Neurotensin receptor 1 is a new therapeutic target for human undifferentiated pleomorphic sarcoma growth.
Tokumoto H; Setoguchi T; Saitoh Y; Sasaki H; Nagano S; Maeda S; Tanimoto A; Taniguchi N
Mol Carcinog; 2019 Dec; 58(12):2230-2240. PubMed ID: 31478563
[TBL] [Abstract][Full Text] [Related]
5. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
7. SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Moody TW; Chan DC; Mantey SA; Moreno P; Jensen RT
Life Sci; 2014 Mar; 100(1):25-34. PubMed ID: 24496038
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
9. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients.
Ouyang Q; Gong X; Xiao H; Zhou J; Xu M; Dai Y; Xu L; Feng H; Cui H; Yi L
Mol Cancer; 2015 Feb; 14():21. PubMed ID: 25644759
[TBL] [Abstract][Full Text] [Related]
10. Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody.
Wu Z; Fournel L; Stadler N; Liu J; Boullier A; Hoyeau N; Fléjou JF; Duchatelle V; Djebrani-Oussedik N; Agopiantz M; Ségal-Bendirdjian E; Gompel A; Alifano M; Melander O; Trédaniel J; Forgez P
Cancer Lett; 2019 Mar; 444():147-161. PubMed ID: 30583074
[TBL] [Abstract][Full Text] [Related]
11. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
Stefanou DT; Bamias A; Episkopou H; Kyrtopoulos SA; Likka M; Kalampokas T; Photiou S; Gavalas N; Sfikakis PP; Dimopoulos MA; Souliotis VL
PLoS One; 2015; 10(2):e0117654. PubMed ID: 25659114
[TBL] [Abstract][Full Text] [Related]
13. Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p.
Ouyang Q; Chen G; Zhou J; Li L; Dong Z; Yang R; Xu L; Cui H; Xu M; Yi L
Neuro Oncol; 2016 Feb; 18(2):216-26. PubMed ID: 26180082
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
15. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
17. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
18. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Shu T; Li Y; Wu X; Li B; Liu Z
Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
[TBL] [Abstract][Full Text] [Related]
20. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
Koussounadis A; Langdon SP; Um I; Kay C; Francis KE; Harrison DJ; Smith VA
BMC Cancer; 2016 Mar; 16():205. PubMed ID: 26964739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
